New Year’s letter — Looking back on 2024 and our New Year’s Resolutions for 2025
2024 has been a very eventful and fruitful year for VasoDynamics!
2nd January 2025 -With significant appreciation to our previous and existing board members for their contributions, we have expanded the expertise on the board and within the operational team to continue our growth.
NG11-2 Programme
We successfully completed the NG11-2 Phase Ib trial for the reduction and prevention of Radiotherapy-Induced Oral Mucositis, and would like to recognise the immense effort and support from our clinical trial team, investigators and research staff and the patients in the NHS trial centres in London, Aberdeen, Belfast and Birmingham. We presented clinical research posters at the ESTRO Annual Meeting 2024 and MASCC Annual Conference 2024, and furthered our engagement with patient groups and Health Care Providers by attending the Oncology Professional Care conference in London, the Head and Neck Cancer conference in Sheffield and the Breast Cancer Symposium 2024 in London.
NG12-1 Programme
We further explored the potential route to early market access, backed by previous positive Phase IIa trial data (Investigator Initiated Trial) generated in the US in our NG12-1 programme for the reduction and prevention of severe radiodermatitis.
NG13-2 Programme
Finally on programme development, we progressed formulation development for our third programme, NG13-2 for the reduction and prevention of chemotherapy-induced alopecia, with follow-on funding support from Good Ventures Foundation.
With excellent support from our CMC and logistics collaborators internationally and locally, we have now secured and future-proofed our IMP supply chain.
With regards to IP, our first formulation and manufacturing method patent (PCT) were smoothly submitted in the EU, USA, Canada, Australia, New Zealand, China, Japan, Korea and Israel, with insightful input from GJE.
Lastly, we joined the Innovate UK Grant consortium for a UK-Taiwan collaboration on developing an AI-embedded Organ-on-Chip technology for high-throughput in vitro drug discovery and screening, which will commence in 2025.
We would like to also recognise the invaluable support provided throughout 2024 by Stevenage Bioscience Catalyst, Taylor Wessing, UK collaborators such as Pharmidex, Agility Life Science, Greenlight Computers, Sciad, Reciprocal Space, Caritas, CHR Life Sciences, Techbio Talent and others.
New Year’s Resolutions for 2025
As we now enter an even more exciting phase of development, we set out our New Year’s Resolutions for 2025:
1) Publish clinical trial results;
2) Continue communication with Regulatory Authorities to confirm future trials’ protocols;
3) Complete market and pricing analysis for three lead indications;
4) Progress the UK-Taiwan collaboration project;
5) Continue to raise funds to support larger scale clinical trials;
6) Continue to explore commercialisation opportunities.
Happy New Year to all our VasoDynamics’ team members, research sites, patient groups, collaborators, friends and supporters, we wish all of you the very best for a successful 2025!
Yours sincerely,
Dr Ningfeng Fiona Li
Co-Founder, CEO
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk
Gary Bower, COO
gary.bower@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.
